Neurometrix Overview
Latest ROE for Neurometrix: -54.54% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-54.54%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, NURO shows a ROE of -54.54%. That is below the Healthcare sector average of 20.77%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 20.77%. Neurometrix is at -54.54%, which is lower that average. That is roughly 362.7% below the sector mean. Use the comparison chart on this page to see how NURO stacks up against individual peers as well.
Check the historical chart to see whether NURO's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Neurometrix with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Neurometrix's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -54.54%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 20.77%, while NURO is at -54.54%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
